Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes
less useful once patients have achieved a hematologic response (HR) (modified by amendment
1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially
in elderly patients.
Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio
of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological
response (modified by amendment 1/03/2017) on Hydroxyurea.